A Phase 2 interventional study of RRx-001 and Cisplatin in Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung and Neuroendocrine Tumors, sponsored by EpicentRx, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by EpicentRx, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Carcinoma, Small Cell with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Carcinoma, Small Cell · United States.
Among the 40 studies in Carcinoma, Small Cell with a site in United States, this one is the 5th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2015, is one of 18 in phase 2, and was the 20th registered.
69 studies on the registry are indexed under Carcinoma, Small Cell; 13 are open to participants now.
Browse Carcinoma, Small Cell studies →3 of the 40 studies in Carcinoma, Small Cell with a site in United States are open now. Recruiting first, the newest first:
SystImmune Inc. · Sites in United States, Australia, Bulgaria and 13 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Andarix Pharmaceuticals · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Carcinoma, Small Cell studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 38 across 61 interventional studies indexed under Carcinoma, Small Cell.
Median enrollment 36 across the 38 interventional studies, 120 across the 2 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 40 have an industry lead sponsor. The 10 most frequent:
EpicentRx, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
EpicentRx, Inc. has 2 studies filed under Carcinoma, Small Cell — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma, Small Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03333616Dana-Farber Cancer InstituteNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | 2026-12-30 |
| NCT04560972City of Hope Medical CenterLB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | 2027-01-27 |
| NCT04696575Roswell Park Cancer InstituteLamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Carcinoma, Small Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.
This is an open label, four 'cohort' study for administration of RRx-001 with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy according to the treatment schedule listed below. Small cell carcinoma and ovarian cohort participants will be randomized to 1 of 2 treatment arms, respectively. Neuroendocrine and NSCLC patients will be enrolled to single arms.
Participants with SCC will receive one of the following; RRx-001 followed by platinum doublet chemotherapy or platinum based chemotherapy alone. HGNEC, RRx-001 followed by platinum doublet chemotherapy. NSCLC, RRx-001 followed by platinum doublet chemotherapy. Participants with Platinum Refractory/Resistant Ovarian and MMMT will receive one of the following, RRx-001 followed by platinum doublet chemotherapy or chemotherapy alone.
Approximately 213 participants will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have or cytologically confirmed advanced or :
High-Grade Neuroendocrine Carcinoma (HGNEC), any organ of origin, including a pathology of neuroendocrine features, in patients previously been treated with chemotherapy Although neuroendocrine tumors may be classified differently based on organ of origin, in the context of this protocol they are defined as high grade on the basis of either
Participants must have adequate organ and marrow function as defined below both prior to administration of RRx-001 and prior to administration of platinum doublet based regimen:
Women of and men with partners of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
Drug: RRx-001 · Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin
Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin · Drug: Irinotecan · Drug: Vinorelbine
RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
Drug: RRx-001 · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed
RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
Drug: RRx-001 · Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin
RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
Drug: RRx-001 · Drug: Carboplatin
Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
Drug: Etoposide · Drug: Carboplatin · Drug: Vinorelbine · Drug: Doxil · Drug: Gemcitabine · Drug: Taxane
Overall Survival
From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.
Time frame: From start of treatment through death for up to 64 months from Start of Treatment.
Overall Response Rate (ORR)
Overall Response Rate (ORR) will be defined as the proportion of patients with a CR or a PR per RECIST v1.1 based upon the best response as assessed; confirmation of response was not required, assessed up to 49 months.
Time frame: Assessed up to 49 months
Disease Control Rate (DCR)
The percentage of patients who have achieved complete response, partial response and stable disease (as per RECIST v1.1), assessed up to 49 months.
Time frame: Assessed up to 49 months
Progression Free Survival (PFS)
Progression-free survival (PFS) will be defined as the elapsed time from the from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 49 months.
Time frame: Assessed up to 49 months
Participants were recruited based on physician referral at 13 academic medical centers between June 2015 and October 2020. The first participant first visit was June 12, 2015 and the last patient last visit was October 8, 2020.
| Milestone | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Screening (Pre-Randomization) (A10) |
|---|---|---|---|---|
| Started | 118 | 0 | 0 | 21 |
| Completed | 94 | 0 | 0 | 13 |
| Not completed | 24 | 0 | 0 | 8 |
| Withdrew: Screen failure | 24 | 0 | 0 | 8 |
| Milestone | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Screening (Pre-Randomization) (A10) |
|---|---|---|---|---|
| Started | 94 | 11 | 2 | 0 |
| Completed | 75 | 7 | 2 | 0 |
| Not completed | 19 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Baseline drop out | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 | 0 | 0 |
| Withdrew: Death | 10 | 1 | 0 | 0 |
From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.
| Months | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| Overall Survival | 6.85 (5.80 to 8.62) | 7.6 (5.00 to NA) | 7.5 (3.00 to NA) |
Overall Response Rate (ORR) will be defined as the proportion of patients with a CR or a PR per RECIST v1.1 based upon the best response as assessed; confirmation of response was not required, assessed up to 49 months.
| Participants | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| Overall Response Rate (ORR) | 32 | 3 | 1 |
The percentage of patients who have achieved complete response, partial response and stable disease (as per RECIST v1.1), assessed up to 49 months.
| Participants | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| Disease Control Rate (DCR) | 42 | 8 | 2 |
Progression-free survival (PFS) will be defined as the elapsed time from the from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 49 months.
| months | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| Progression Free Survival (PFS) | 5.87 (4.46 to 7.54) | 6.50 (NA to NA) | 12 (NA to NA) |
Collected over Adverse Events were collected beginning at baseline through end of treatment (28 days after last dose of study drug), up to 64 months. All-Cause Mortality was assessed from baseline through 28 days after last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RRx-001 + Platinum Doublet (A01-09) | 89/89 (100%) | 55/89 (61.8%) | 89/89 (100%) |
| RRx-001 + Platinum + RRx-001 (A10) | 10/10 (100%) | 6/10 (60%) | 10/10 (100%) |
| Investigator's Choice (A10) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Event | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| Inappropriate antidiuretic hormone secretionMetabolism and nutrition disorders | 0/89 | 2/10 | 2/2 |
| AnaemiaBlood and lymphatic system disorders | 4/89 | 1/10 | 1/2 |
| EmbolismVascular disorders | 1/89 | 0/10 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/89 | 1/10 | 0/2 |
| Atrial fibrillationCardiac disorders | 2/89 | 1/10 | 0/2 |
| Intestinal perforationGastrointestinal disorders | 0/89 | 1/10 | 0/2 |
| Small Intestinal ObstructionGastrointestinal disorders | 3/89 | 1/10 | 0/2 |
| Mental status changesPsychiatric disorders | 1/89 | 1/10 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 1/89 | 1/10 | 0/2 |
| Urinary tract obstructionRenal and urinary disorders | 1/89 | 1/10 | 0/2 |
| Event | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/89 | 8/10 | 2/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/89 | 4/10 | 1/2 |
| ConstipationGastrointestinal disorders | 20/89 | 2/10 | 1/2 |
| NauseaGastrointestinal disorders | 12/89 | 4/10 | 1/2 |
| FatigueGeneral disorders | 18/89 | 4/10 | 1/2 |
| Infusion related reactionInvestigations | 18/89 | 4/10 | 1/2 |
| NeutropeniaBlood and lymphatic system disorders | 9/89 | 3/10 | 0/2 |
| Abdominal painGastrointestinal disorders | 9/89 | 3/10 | 0/2 |
| VomitingGastrointestinal disorders | 5/89 | 2/10 | 0/2 |
| HeadacheNervous system disorders | 8/89 | 2/10 | 0/2 |
Safety Population comprises all subjects who are randomized and received at least 1 dose of study drug and will be used for all analyses of safety. Analysis is based on actual treatment group
| Age, Continuous(years) | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Total |
|---|---|---|---|---|
| Mean | 61.4 ± 11.3 | 61.3 ± 6.1 | 75.0 ± 2.8 | 61.6 ± 10.9 |
| Sex: Female, Male(Participants) | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Total |
|---|---|---|---|---|
| Female | 48 | 8 | 0 | 56 |
| Male | 46 | 3 | 2 | 51 |
| Ethnicity (NIH/OMB)(Participants) | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 0 | 4 |
| Not Hispanic or Latino | 88 | 10 | 2 | 100 |
| Unknown or Not Reported | 3 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 7 | 1 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 3 |
| Black or African American | 10 | 0 | 0 | 10 |
| White | 74 | 9 | 2 | 85 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | RRx-001 + Platinum Doublet (A01-09) | RRx-001 + Platinum + RRx-001 (A10) | Investigator's Choice (A10) | Total |
|---|---|---|---|---|
| United States | 94 | 11 | 2 | 107 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Dec 2021, 78 months.
Results were first posted in Mar 2025, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: RRx-001 · Cisplatin · Etoposide
EpicentRx, Inc.